Cargando…

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies

OBJECTIVE: In this study, we determined whether Helicobacter pylori (H. pylori) infection dampens the efficacy of cancer immunotherapies. DESIGN: Using mouse models, we evaluated whether immune checkpoint inhibitors or vaccine-based immunotherapies are effective in reducing tumour volumes of H. pylo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oster, Paul, Vaillant, Laurie, Riva, Erika, McMillan, Brynn, Begka, Christina, Truntzer, Caroline, Richard, Corentin, Leblond, Marine M, Messaoudene, Meriem, Machremi, Elisavet, Limagne, Emeric, Ghiringhelli, Francois, Routy, Bertrand, Verdeil, Gregory, Velin, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Helicobacter Pylori
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862014/ https://www.ncbi.nlm.nih.gov/pubmed/34253574 http://dx.doi.org/10.1136/gutjnl-2020-323392

Ejemplares similares

Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines
por: Aebischer, T, et al.
Publicado: (2008)

Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7
por: Yin, Yinfei, et al.
Publicado: (2010)

Protein kinase C isozymes regulate matrix metalloproteinase-1 expression and cell invasion in Helicobacter pylori infection
por: Sokolova, Olga, et al.
Publicado: (2013)

The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention
por: Lee, Yi-Chia, et al.
Publicado: (2013)

CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa
por: Cook, Katherine W, et al.
Publicado: (2014)

Progressive genomic convergence of two Helicobacter pylori strains during mixed infection of a patient with chronic gastritis
por: Cao, Qizhi, et al.
Publicado: (2015)

A pro-inflammatory role for Th22 cells in Helicobacter pylori-associated gastritis
por: Zhuang, Yuan, et al.
Publicado: (2015)

A novel human gastric primary cell culture system for modelling Helicobacter pylori infection in vitro
por: Schlaermann, Philipp, et al.
Publicado: (2016)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial
por: Liou, Jyh-Ming, et al.
Publicado: (2016)

Pan-genomic analyses identify key Helicobacter pylori pathogenic loci modified by carcinogenic host microenvironments
por: Noto, Jennifer M, et al.
Publicado: (2018)

USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis
por: Costa, Lionel, et al.
Publicado: (2020)

Helicobacter pylori infection and micronutrient deficiency in pregnant women: a systematic review and meta-analysis
por: Afsar, Md. Nure Alam, et al.
Publicado: (2020)

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
por: Suzuki, Sho, et al.
Publicado: (2020)

Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis
por: Chang, Yen-Lin, et al.
Publicado: (2020)

Assessment of Helicobacter pylori status by examination of gastric mucosal patterns: diagnostic accuracy of white-light endoscopy and narrow-band imaging
por: Glover, Ben, et al.
Publicado: (2021)

Cost-effectiveness modelling of use of urea breath test for the management of Helicobacter pylori-related dyspepsia and peptic ulcer in the UK
por: Pritchard, D. Mark, et al.
Publicado: (2021)

Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention
por: Zhou, Xian-Zhu, et al.
Publicado: (2023)

Helicobacter pylori
por: Harris, A. W. (Adam W.), 1963-
Publicado: (1996)

The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection
por: Oster, Paul, et al.
Publicado: (2022)

GM‐CSF is key in the efficacy of vaccine‐induced reduction of Helicobacter pylori infection
por: Vaillant, Laurie, et al.
Publicado: (2022)

High-dose dual therapy versus culture-based susceptibility-guided therapy as a rescue regimen for Helicobacter pylori infection: a randomized controlled trial
por: Zhao, Zhe, et al.
Publicado: (2022)

Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial
por: Mei, Hao, et al.
Publicado: (2022)

Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances
por: Shih, Chih-An, et al.
Publicado: (2022)

High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis
por: Zhou, Ben-Gang, et al.
Publicado: (2023)

The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study
por: He, Xiao-Jian, et al.
Publicado: (2023)

Implications of the paradigm shift in management of Helicobacter pylori infections
por: Graham, David Y.
Publicado: (2023)

Therapeutic eradication choices in Helicobacter pylori infection in children
por: Manfredi, Marco, et al.
Publicado: (2023)

Dietary habits and Helicobacter pylori infection: is there an association?
por: Soares, Giovana Alice Sampaio, et al.
Publicado: (2023)

Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection
por: Moss, Steven F., et al.
Publicado: (2023)

Helicobacter pylori in children: think before you kill the bug!
por: Ravikumara, M
Publicado: (2023)

Adequate amounts of probiotics increase the success rate of Helicobacter pylori eradication therapy in children
por: Kakiuchi, Toshihiko
Publicado: (2023)

Update on the second-line treatment of Helicobacter pylori infection: a narrative review
por: Shih, Chih-An, et al.
Publicado: (2023)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

Rescue therapy for refractory Helicobacter pylori infection: current status and future concepts
por: Wang, Song-Wei, et al.
Publicado: (2023)

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers
por: Medjebar, Soleine, et al.
Publicado: (2020)

Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients
por: Blaecher, C, et al.
Publicado: (2013)

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
por: Limagne, Emeric, et al.
Publicado: (2019)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer
por: Klopfenstein, Quentin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jccni9sqj9n3ebb5geh6t3jv40